Ashkon Software



CYTR Stock - CytRx Corporation

CYTR Intraday Chart

CYTR Profile

CytRx Corporation logo

CytRx Corporation (CYTR) is a biopharmaceutical company that develops and commercializes innovative cancer therapies. The company's lead product candidate, aldoxorubicin, is a tumor-targeted chemotherapy that is designed to selectively deliver the drug to cancer cells while minimizing damage to healthy tissue.

CytRx is also developing other drug candidates, including INNO-206, a tumor-targeted version of the chemotherapy drug doxorubicin, and its LADR (Linker Activated Drug Release) platform technology, which is designed to improve the delivery of cancer drugs.

CytRx was founded in 1985 and is headquartered in Los Angeles, California. Tthe company was facing some challenges related to the clinical development of its lead product candidate, aldoxorubicin. The company had experienced some setbacks in its clinical trials, which had led to delays in the development and commercialization of the drug. The company's revenue for the fiscal year 2020 was $3.3 million, representing a decrease from $5.7 million in the previous year. Net loss for the same period was $14.1 million, a decline from a net loss of $13.3 million in the previous year.

CytRx has a market capitalization of approximately $25 million as of my knowledge cutoff of September 2021, and its stock is listed on the OTC Pink market under the ticker symbol CYTR.

The biopharmaceutical industry is subject to various risks, including regulatory risks, competitive risks, and clinical trial risks. However, CytRx's focus on developing innovative cancer therapies and its efforts to address its clinical development challenges should position it for improved performance in


Copyright © 2000-2024, Ashkon Software LLC
Privacy Policy | Refund Policy | Disclaimer